Citigroup’s Senti Biosciences Holdings SNTI Stock Holding History

Citigroup’s Portfolio SNTI Stock Details SNTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$1	–	6436
2025 Q3	$1	Buy	+1	New	+$2	﹤0.01%	6044
2025 Q1	–	Sell	-1	Closed	-$4	–	5931
2024 Q4	$4	Sell	1 -165	-99%	-$527	﹤0.01%	5791
2024 Q3	$375	Buy	+166	New	+$439	﹤0.01%	5495
2024 Q2	–	Sell	-134	Closed	-$505	–	5767
2024 Q1	$505	Buy	+134	New	+$599	﹤0.01%	5458
2023 Q2	–	Sell	-1,447	Closed	-$17.1K	–	5716
2023 Q1	$17.1K	Buy	+1,447	New	+$22.5K	﹤0.01%	4560

Other funds holding SNTI

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

MSOP GP Menlo Park, California $439M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's SNTI Position: Q4 2025 in Review

Citigroup sold out of Senti Biosciences Holdings (SNTI) in Q4 2025, closing a stake of 1 share — an estimated $1 sold.

Citigroup first reported a position in SNTI in Q1 2023 and held it in 5 quarters. The position peaked at $17.1K in Q1 2023. 15 funds tracked by Wall St. Rank hold SNTI as of Q4 2025.

Citigroup reported no remaining Senti Biosciences Holdings position as of Q4 2025 after selling out during the quarter.
Citigroup sold 1 Senti Biosciences Holdings share in Q4 2025, an estimated $1.
Citigroup first reported a position in Senti Biosciences Holdings in Q1 2023 and held it in 5 quarters.
Citigroup's Senti Biosciences Holdings position peaked at $17.1K in Q1 2023.
15 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.